肖志堅，主任醫師，教授，博士生導師，副所院長、MDS診療中心主任，病理中心主任。主要研究髓系腫瘤發病分子機制和臨床診治新策略。主持國家級、省部級、院校級課題共計27項。牽頭制定了疾病診治指南/共識共8部，制定了國家衛健委頒布的骨髓增生異常綜合征（MDS）和骨髓增殖性腫瘤（MPN）的診療路徑。在國際頂尖期刊N Engl J Med、Cancer Discov、Leukemia、Blood等雜志發表多篇論文，相關研究成果被國際指南引用?，F為我國MDS和MPN研究領域的領軍人物。
肖志堅
中國醫學科學院血液病醫院（中國醫學科學院血液學研究所）
教授
2022-01-01
臨床醫學
內科學（血液?。?/p>
zjxiao@ihcams.ac.cn
肖志堅，主任醫師，教授，博士生導師，副所院長、MDS診療中心主任，病理中心主任。主要研究髓系腫瘤發病分子機制和臨床診治新策略。主持國家級、省部級、院校級課題共計27項。牽頭制定了疾病診治指南/共識共8部，制定了國家衛健委頒布的骨髓增生異常綜合征（MDS）和骨髓增殖性腫瘤（MPN）的診療路徑。在國際頂尖期刊N Engl J Med、Cancer Discov、Leukemia、Blood等雜志發表多篇論文，相關研究成果被國際指南引用?，F為我國MDS和MPN研究領域的領軍人物。
髓系腫瘤發病分子機制和臨床診治新策略。
1. Liu YC#, Kwon J#, Fabiani E#, Xiao Z#, Liu YV, Follo MY, Liu J, Huang H, Gao C, Liu J, Falconi G, Valentini L, Gurnari C, Finelli C, Cocco L, Liu JH, Jones AI, Yang J, Yang H, Thoms JAI, Unnikrishnan A, Pimanda JE, Pan R, Bassal MA, Voso MT, Tenen DG*, Chai L*. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. N Engl J Med. 2022,386(21):1998-2010. (IF=176.079)
2. Liu D#, Xu Z#, Zhang P, Qin T, Sun X, Qu S, Pan L, Ma J, Cai W, Liu J, Wang H, Sun Q, Shi Z, Huang H, Huang G, Gale RP, Li B*, Rampal RK*, Xiao Z*. Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center. Haematologica. 2022,107(4):991-995. (IF=11.0479)
3. Liu D#, Li B, Xu Z, Zhang P, Qin T, Qu S, Pan L, Sun X, Shi Z, Huang H, Wang H, Gale RP, Xiao Z*. RBC distribution width predicts thrombosis risk in polycythemia vera. Leukemia. 2022,36(2):566-568. (IF=12.883)
4. Liu D#, Xu Z, Zhang P, Qin T, Li B, Qu S, Pan L, Cai W, Liu J, Wang H, Sun Q, Sun X, Jiao M, Gao Q, Shi Z, Huang H, Huang G, Gale RP, Xiao Z*. Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera. Blood Cancer J. 2021,11(9):154. (IF=9.812)
5. Huang H#, Xu C#, Gao J#, Li B, Qin T, Xu Z, Ren S, Zhang Y, Jiao M, Qu S, Pan L, Hu N, Liu J, Cai W, Zhang Y, Wu D, Zhang P, Gale RP, Huang G, Zhou J, Shi L*, Xiao Z*. Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre. Blood Cancer J. 2020,10(8):83. (IF=11.037)
6. Hayashi Y#, Zhang Y#, Yokota A#, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger GM, Wang J, Dong Y, Zhou Y, Wang J, Wu L, Bu J, Chen A, Zhao X, Sun X, Chetal K, Olsson A, Watanabe M, Romick-Rosendale LE, Harada H, Shih LY, Tse W, Bridges JP, Caligiuri MA, Huang T, Zheng Y, Witte DP, Wang QF, Qu CK, Salomonis N, Grimes HL, Nimer SD, Xiao Z*, Huang G*. Pathobiologic Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Cancer Discov, 2018, 8(11):1438-1457. (IF=26.37)
7. Luo X#, Xu Z#, Li B#, Qin T, Zhang P, Zhang H, Fang L, Pan L, Hu N, Qu S, Zhang Y, Huang G, Peter Gale R, Xiao Z*. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer J. 2018,8(1):9. (IF=7.895, R)
8. Wang J#, Xu Z#, Liu L#, Gale RP, Cross NC, Jones AV, Qin T, Ai X, Xu J, Zhang T, Sun X, Li Q, Zhang P, Zhang Y, Xiao Z*. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia,2013,27(8):1763-1767. (IF=9.379)
9. Xu Z#, Gale RP, Zhang Y, Qin T, Chen H, Zhang P, Zhang T, Liu L, Qu S, Xiao Z*. Unique features of primary myelofibrosis in Chinese. Blood. 2012,119(11):2469-73. (IF=9.060, F1000)
10. Xiao Z#*, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma. 2002,43(9):1763-8. (IF=1.335, C100)